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transition. In all sub-populations, cardiovascular disease is a 
major cause of morbidity and mortality. Every day, approxi-
mately 80 people die of myocardial infarction or heart failure, 
while another 60 die due to stroke.(4) The INTERHEART Africa 
study indicated that more premature acute myocardial infarc-
tions occur in sub-Saharan Africa than in any other of the 
52 countries participating in the INTERHEART study.(5,6) This 
statistic reflects a lack of prevention, early detection and 
effective management of cardiovascular risk factors in the 
countries of this region.(5) In particular, in the black population, 
with increasing urbanisation and adoption of an unhealthy 
lifestyle, the prevalence of cardiovascular disease (CVD) and 
the incidence of premature death are likely to continue to 
increase.(4) Consequently, the timely introduction of lifestyle 
modification, early diagnosis and effective management of 
INTRODUCTION
In 2003, the South African Heart Association (SA Heart) and 
the Lipid and Atherosclerosis Society of Southern Africa 
(LASSA) officially adopted the European Guidelines for the 
Prevention of Cardiovascular Disease(1) to replace the South 
African Lipid Guidelines published in 2000.(2) The European 
document has recently been updated with the publication of 
the European Society of Cardiology (ESC)/European Society of 
Atherosclerosis (EAS) Guideline for the Management of 
Dyslipidaemia in 2011.(3) This consensus statement promotes 
current best management of dyslipidaemia and should be 
adopted by all health care professionals in South Africa.
South Africa is a multi-ethnic society, with a large range of 
cultures and lifestyles at different stages of epidemiological 
                            The European Society of Cardiology together with the European Atherosclerosis Society 
published updated dyslipidaemia guidelines in 2011. SA Heart and the Lipid and Atherosclerosis Society of 
Southern Africa officially adopt these guidelines. This statement adapts aspects of the guidelines to the South 
African situation. Using the updated Framingham risk charts, interventional strategies are based according to 
the cardiovascular risk score and low-density lipoprotein cholesterol (LDL-C) levels. The Framingham risk score 
refers to the 10-year risk of any cardiovascular event, and includes four categories of risk. Treatment targets are 
those of the European guidelines. The LDL-C goal is 1.8mmol/l for the very high-risk group (>30%), 2.5mmol/l 
for the high-risk group (15 - 30%), and 3mmol/l for those below 15% risk. Intensive management of dyslipidaemia 
in South Africa will significantly reduce the cardiovascular disease health burden. SAHeart 2012; 9:106-117
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CVD risk factors are essential to curb the CVD epidemic of 
that has been seen in other countries.(5)
WHEN TO USE THE CARDIOVASCULAR 
RISK SCORE
Very high-risk individuals do not require risk scoring
Individuals who are considered to be at very high risk of cardio-
vascular events are listed in Table 1. Patients in this group do 
not require cardiovascular risk scoring, because the risk score 
will be an underestimate in these settings.
Individuals who do not fall into the very high-risk 
category
Risk scoring using well-documented key risk factors is appro-
priate to estimate the total cardiovascular risk in asymptomatic 
adults. Furthermore, risk scoring is especially important in 
individuals with the following:
 ■ hypertension and/or on anti-hypertensive medication;
 ■ smoking: cigarette smoking is defined as any cigarette 
smoking in the past month or a history of 20 cigarettes per 
day for 10 years (10 pack years);
 ■ body mass index (BMI) ≥30kg/m2 or waist circumference 
>94cm for men, >80cm for women;
 ■ family history of premature CVD (male before 55 years of 
age, female before 60 years); and
 ■ auto-immune chronic inflammatory disease, e.g. rheumatoid 
arthritis, systemic lupus erythematosus or psoriasis.
WHEN TO START SCREENING
In South Africa, because the prevalence of familial hyper-
cholesterolaemia is as high as 1 in 100 in some communities, 
each individual should be tested, preferably with a full lipogram 
or at least total cholesterol/low-density lipoprotein cholesterol 
(TC/LDL-C), at least once in young adulthood (from 20 years 
of age). Particular attention should be paid to individuals with 
other risk factors for CVD.
HOW TO SCREEN: USING THE FRAMINGHAM 
RISK SCORE
The European guidelines use the Systematic Coronary Risk 
Estimation (SCORE) system to estimate cardiovascular risk. 
Because this scoring system is based on an exclusively European 
population, it may not accurately reflect coronary risk in South 
Africa. While it is recognised that it would be impossible to 
accurately estimate risk in all South African subpopulations with 
a single data set, the Adult Treatment Panel (ATP) III 
Framingham risk tables,(7) which provide an estimate of the 
10-year risk of CHD, have been validated in white and 
black populations in the USA and are transportable to other 
culturally diverse populations. Consequently, we considered 
this approach to be more appropriate for South Africa. 
Nevertheless, these risk tables are likely to underestimate risk 
in South African black and Indian patients. The Framingham 
CHD tables may also underestimate total CVD risk in middle-
aged and older women, whose risk of stroke and heart failure 
is typically higher than that of CHD. Even when multiple 
elevated risk factors are present, it is difficult for a woman 
younger than 75 years to exceed a 10% predicted risk for 
CHD, precluding her from qualification for more aggressive 
CVD prevention.(8) Consequently, more recent Framingham 
equations predict 10-year total CVD risk (including CHD, 
stroke, transient ischaemic attack and heart failure).(8,9)
The updated Framingham CVD risk tables for men and women 
and an algorithm for management and cholesterol goals have 
been incorporated into these recommendations (Appendix 1).
TABLE 1:  Subjects considered to be at very high risk of 
cardiovascular events
Established atherosclerotic disease, i.e.
- coronary artery disease
- cerebrovascular disease
- peripheral arterial disease
Type 2 diabetes
Type 1 diabetes with micro-albuminuria or proteinuria
Genetic dyslipidaemia, e.g. familial hypercholesterolaemia
Chronic kidney disease (GFR <60ml/min/1.73m2)
GFR = glomerular filtration rate.
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MEASURING LIPIDS
Low-density lipoprotein cholesterol
LDL-C is preferred when deciding on treatment and assessing 
its effect. LDL-C is used in preference to other tests as it is 
modifiable by treatment and the beneficial effects of lowering 
LDL-C are known. LDL-C may be measured directly or 
calculated from the Friedewald equation (in mmol/l) (LDL-C = 
TC – high-density lipoprotein cholesterol (HDL-C) – triglyceride 
(TG)/2.2), provided the triglycerides do not exceed 4.5mmol/l.
Total cholesterol
Once the relationship between on-treatment TC and LDL-C is 
known, it may be appropriate to monitor TC only. TC may 
be used as an alternative for screening, risk assessment and 
monitoring of treatment efficacy if there are cost constraints 
or if there is difficulty in obtaining either direct or indirect 
LDL-C values.
Equivalent target values for TC are:
 ■ TC = 4.5mmol/l is approximately equivalent to 
LDL-C = 2.5mmol/l
 ■ TC = 4.0mmol/l is approximately equivalent to 
LDL-C = 1.8mmol/l
If TC values remain uncontrolled and LDL-C measurement 
is unavailable, the patient should be referred to a specialist 
physician.
Cost-effective testing
A full lipogram (TC, HDL-C, LDL-C and triglycerides) is recom-
mended for initial diagnosis of dyslipidaemia. In patients with 
pure hypercholesterolaemia, LDL-C alone is adequate for 
follow-up, but a full lipogram is recommended where increased 
LDL-C is not the only abnormality in the lipid profile. After 
initiating therapeutic lifestyle change (TLC) alone, follow-up 
testing should be performed every 6 months. After initiating 
pharmacotherapy, changing the dose or changing the specific 
drug prescribed, testing should be repeated at 8 (±4) weeks 
and thereafter, once the patient is at goal, every 6 months.
Point-of-care fi nger prick testing
Various point-of-care tests are available. They provide various 
results, ranging from TC alone to a full lipogram. Where finger 
prick testing is performed, the facility should ensure that 
adequate quality controls are in place, that the test strips and 
devices are stored under appropriate conditions of tempera-
ture, humidity and light, and that precautions are taken to 
perform the test properly, with an adequate blood sample 
volume and without contamination.(10) The finger should not be 
squeezed or “milked”, as this will give inaccurate results.
Finger prick testing is appropriate for screening and follow-up 
to determine where advice on lifestyle intervention is required 
(e.g. TC >5mmol/l), but is not appropriate to commit a patient 
to a lifetime of therapy. Where a screening finger prick TC 
measurement is high (>5mmol/l), the patient should be 
encouraged to discuss their finger prick screening result with 
their doctor, who should have a full laboratory-performed 
fasting lipogram done and then perform a full cardiovascular risk 
assessment. Because inappropriately low results are a concern, 
TC <2.5mmol/l on a finger prick test should be confirmed. 
Finger prick testing that measures TC alone will not detect 
raised triglycerides.
Additional testing
The use of novel biomarkers of CVD (e.g. high-sensitivity 
C-reactive protein (hsCRP)) and imaging technologies (e.g. 
coronary calcium scoring, carotid intima-media thickness) is not 
recommended routinely and should be reserved to refine risk 
assessment in patients considered to be at moderate risk where 
there is uncertainty about whether to initiate drug therapy.(8) 
It should be noted that hsCRP is a nonspecific inflammatory 
marker that may be elevated from many causes (e.g. acute 
infections or non-infectious inflammatory disorders). Measuring 
lipoprotein (a) (Lp(a)) is only appropriate in high CVD risk 
subjects and/or when there is a family history of premature 
CVD. When Lp(a) is used as a risk marker, the cut-off value 
is >50mg/dl.
Secondary dyslipidaemias
Dyslipidaemia may occur in response to another condition or 
treatment. Table 2 lists those encountered most commonly. 
The appropriate diagnostic tests should be performed when 
secondary dyslipidaemia is suspected and the underlying 
abnormality treated.
STRATEGY FOR INTERVENTION
The risk levels determined for the SCORE system refer to the 
10-year risk of a fatal CVD event, whereas the Framingham 
scoring system refers to the 10-year risk of any CVD event. Risk 
thresholds for the Framingham score are therefore 
approximately 3 times those for SCORE.
Table 3 sets out the recommended appropriate intervention 
strategies according to the percentage risk calculated from the 
Framingham risk score and the LDL-C value obtained.
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TREATMENT TARGETS
Although we recommend the use of the Framingham risk charts 
to estimate cardiovascular risk, the management of patients, 
once risk has been determined, and the goals of therapy, are 
those of the European guidelines.
LDL-C goals for patients at different levels of Framingham risk 
are listed in Table 4.
MANAGEMENT OF DYSLIPIDAEMIA
Because the total cardiovascular risk is the product of a number 
of risk factors, the treatment of dyslipidaemia must always be 
seen within the broader framework of cardiovascular disease 
prevention.
Lifestyle modifi cation
It should be emphasised that the cornerstone of any programme 
to reduce cardiovascular risk is TLC (healthy diet, regular 
exercise). In order for the changes to be sustainable, dietary 
and exercise advice must be practical and tailored specifically to 
the individual’s personal and cultural preferences.(11) Diets may 
need to be modified for people with unusual or specific 
disorders (e.g. hypertriglyceridaemia) and referral to a dietician 
and fitness professional is encouraged. An example of lifestyle 
and dietary advice that is relevant to the South African 
population is listed in Appendix 2.
Dietary supplements
Epidemiological and interventional studies support the role of 
healthy dietary choices as a whole to help reduce the risk of 
cardiovascular events. However, insufficient evidence exists to 
recommend the use of dietary supplements in patients with 
dyslipidaemia. While some dietary supplements have been 
shown to influence plasma lipids, there are no outcomes data 
that show benefits with regard to CVD prevention. Conversely, 
there is evidence that some supplements may be harmful to 
health and may interact with prescription medicines.(12,13) 
Consumers should be advised to beware of unsubstantiated 
advertising claims relating to long-term health benefits.
Although there are no known risks associated with its use, the 
routine use of coenzyme Q10 to reduce statin-related myalgia 
or myopathy is not supported by systematic reviews of the 
medical literature.(14,15)
Statin therapy
Statins have demonstrated effectiveness in both primary and 
secondary prevention. The effect is dependent on the extent to 
which LDL-C is lowered and not on the type of statin used. At 
their maximum doses, the various statins differ in their capacity 
to lower LDL-C.
TABLE 2:  Secondary causes of dyslipidaemia
Diabetes mellitus
Hypothyroidism
Liver disease
Renal disease, e.g. nephrotic syndrome
Alcohol excess
Medications:
- progestins
- steroids
- antiretroviral agents
- retinoids
TABLE 3: Intervention strategies as a function of Framingham total CVD risk score and LDL-C levels(3)*
  LDL-C levels 
Total CVD risk score#  <1.8mmol/l 1.8 - <2.5mmol/l 2.5 - 4.9mmol/l >4.9mmol/l
<3% No lipid intervention No lipid intervention Lifestyle intervention Lifestyle intervention, consider
Low risk     drug if uncontrolled
3 - 15% Lifestyle intervention Lifestyle intervention Lifestyle intervention, consider  Lifestyle intervention, consider
Moderate risk    drug if uncontrolled drug if uncontrolled
15 - 30% Lifestyle intervention,  Lifestyle intervention, Lifestyle intervention and Lifestyle intervention and
High risk consider drug†  consider drug†  immediate drug intervention  immediate drug intervention
>30% Lifestyle intervention,  Lifestyle intervention and Lifestyle intervention and Lifestyle intervention and
Very high risk consider drug†  immediate drug intervention  immediate drug intervention  immediate drug intervention
*Based on Table 3 from Reiner Ž, et al., Eur Heart J 2011;32:1769-1818.(3)  #Based on the Framingham CVD risk tables.(9)
†In patients with myocardial infarction (MI), statin therapy should be considered regardless of LDL-C levels.
CVD = cardiovascular disease.  LDL-C = low-density lipoprotein cholesterol.
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For every mmol/l reduction in LDL-C there is a:
 ■ 10% reduction in mortality
 ■ 20% reduction in all-cause morbidity
 ■ 23% reduction in major cardiac events
 ■ 17% reduction in stroke
The effect of statin therapy is similar in all patient subgroups 
and becomes significant after 1 year, increasing progressively 
thereafter.
High-dose simvastatin treatment
Although the incidence of myopathy is very low for all the 
statins, it is approximately 3 times as high with 80mg simva-
statin compared with maximum doses of atorvastatin and 
rosuvastatin. Accordingly, the American Food and Drug Admi-
nistration (FDA) has mandated safety-labelling changes for 
medicines containing simvastatin, which include the following 
recommendations:(16)
 ■ The use of 80mg simvastatin should be restricted to those 
who have been using the dose chronically (longer than 12 
months), without signs or symptoms of myopathy.
 ■ Patients who are using simvastatin 80mg and who need to 
start taking another drug that may interact with simvastatin 
should be switched to an alternative statin with a lower risk 
of drug interactions, such as rosuvastatin or atorvastatin.
 ■ Patients who do not reach their LDL-C goal with 40mg 
simvastatin should be switched to an appropriate alternative 
more potent statin with a lower potential for myopathy.
 ■ To reduce the incidence of myopathy:
-   do not exceed 10mg simvastatin with amiodarone, 
verapamil, or diltiazem
-  do not exceed 20mg simvastatin with amlodipine
-   simvastatin is contraindicated with azole antifungals, 
macrolide antibiotics, HIV protease inhibitors, gemfibrozil, 
cyclosporine and danazol.
Statin toxicity
When used in appropriate patients, statins are remarkably safe 
drugs and the benefits of cardiovascular protection far outweigh 
the potential for toxicity. However, patients should be 
encouraged to make and sustain healthy lifestyle choices and 
the lowest dose of statin to achieve LDL-C target should be 
used.
Statin-related myalgia and rhabdomyolysis
The presence of any musculoskeletal pain should be docu-
mented before starting statin therapy to facilitate the recognition 
of statin-induced myalgia during treatment.
A creatine kinase (CK) measurement prior to commencing 
statin treatment is recommended. Statins should not be started 
if the CK is >5 times the upper limit of normal (ULN). Routine 
CK monitoring is not necessary during treatment, unless the 
patient develops myalgia. Increased vigilance regarding CK and 
myopathy is necessary in the elderly, in those on concomitant 
interfering treatment or on multiple medications, and in the 
presence of liver or renal disease.
If myalgia develops and the CK is >5 times the ULN:
 ■ stop treatment
 ■ check renal function
 ■ monitor CK every 2 weeks
 ■ consider causes of transient CK elevation, e.g. exercise
 ■ consider alternative causes of myopathy
If myalgia develops and the CK is <5 times the ULN:
 ■ monitor symptoms
 ■ monitor CK regularly
If the CK is <5 times the ULN and there are no muscle 
symptoms:
 ■ continue statin
 ■ alert patient to report symptoms
 ■ consider monitoring CK
TABLE 4: LDL-C treatment targets
 Total Framingham CVD risk (%) ESC/EAS risk classifi cation ESC/EAS LDL-C target
<3 Low risk <3.0mmol/l
3 - 15 Moderate risk <3.0mmol/l
15 - 30 High risk <2.5mmol/l
>30 Very high risk <1.8mmol/l
LDL-C = low-density lipoprotein cholesterol.  CVD = cardiovascular disease.  ESC = European Society of Cardiology.  EAS = European Society of Atherosclerosis.
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The incidence of rhabdomyolysis is very low.
In patients who are intolerant to statin therapy, potent statins, 
such as atorvastatin or rosuvastatin, may be used on alternate 
days (e.g. Monday, Wednesday, Friday) or even less frequently 
to reduce side-effects.(17) Alternatively, a combination therapy 
of a low-dose statin with a lipid-lowering drug of another class 
(e.g. ezetimibe) can be considered.
Statin-induced rises in alanine aminotransferase
Baseline alanine aminotransferase (ALT) measurement should 
be performed before initiating treatment with a statin. If the 
ALT is normal, it does not need to be repeated. Raised ALT 
does not exclude statin therapy, where treatment should be 
individualised. Alternative reasons for raised ALT (e.g. haemo-
chromatosis, fatty liver) should be investigated where necessary.
If the ALT is raised <3 times the ULN while on treatment, 
continue the statin and recheck ALT in 4 - 6 weeks. If the ALT 
is raised >3 times the ULN on treatment, stop the statin and 
repeat ALT in 4 - 6 weeks. Cautious reintroduction of the statin 
can be considered once the ALT has returned to normal.
New-onset diabetes
Recent meta-analyses have demonstrated a very small increase 
in the risk of new-onset diabetes associated with statin use, 
notably in patients treated with intensive-dose statin therapy 
and in older patients.(18,19) However, this small potential adverse 
risk is outweighed by the absolute reduction in CV events and 
should not discourage initiation of statin therapy.(3,19,20)
Scheme for introducing statin treatment
 ■ First evaluate the risk
 ■ Involve the patient in CV risk management decisions
 ■ Identify the appropriate LDL-C target
 ■ Calculate % reduction in LDL-C required to reach target
 ■ Choose the statin (and dose) able to achieve the desired 
reduction (Table 5)
 ■ It is mandatory to up-titrate the dose to achieve the LDL-C 
target
 ■ If target is not reached at maximal dose, consider a more 
potent statin or add a lipid-lowering drug from another 
class
 ■ The final statin choice will be influenced by concomitant 
conditions, concomitant drug therapy and tolerability
Other cholesterol-lowering agents
The cholesterol absorption inhibitor ezetimibe in combination 
with simvastatin was shown to reduce major atherosclerotic 
events in patients with advanced chronic kidney disease.(22) 
Although no other outcome studies have been completed, 
ezetimibe is recommended:
 ■ as second-line treatment in combination with a statin when 
the LDL-C target is not reached at the highest tolerated 
statin dose;
 ■ when there is intolerance to statins; and
 ■ when there is a contraindication to a statin.
Bile acid sequestrants and nicotinic acid have cholesterol-
lowering properties. They may occasionally be useful alone or 
in combination with statin therapy. However, their side-effects 
limit wider application.
Treatment directed at other components of the lipid 
profi le
Whereas low levels of HDL-C and high levels of TG are 
undoubtedly associated with a higher CVD risk, no currently 
available treatment directed at reversing these changes has 
been shown to significantly benefit cardiovascular outcome.
A high triglyceride level, particularly if >10mmol/l, can result in 
acute pancreatitis and should be treated without delay.
SPECIAL CIRCUMSTANCES
Metabolic syndrome
The European Guidelines recognise the importance of 
identifying patients with the metabolic syndrome, who are at 
increased risk of cardiovascular disease. The presence of the 
syndrome approximately doubles the risk of cardiovascular 
disease. Lifestyle changes, particularly reducing body weight and 
increasing physical activity, are the cornerstone of management 
of the metabolic syndrome.(23)
Acute coronary syndromes
A lipid profile should be obtained at the time of admission in 
patients presenting with acute coronary syndromes (ACS). 
They should be treated with high-dose statin therapy during 
their acute care and the statin dose should be adjusted at the 
time of discharge according to the admission lipid profile.
HIV infection
Dyslipidaemia frequently accompanies HIV and may be 
aggravated by antiretroviral drugs (ARVs). While there is limited 
information, particularly in South Africa, it is important to 
measure lipids in patients with HIV and estimate their CVD 
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risk, and a full lipogram should be performed before initiating 
ARV treatment. The Framingham tables will generally under-
estimate CVD risk in this population. In patients with high lipid 
levels already on ARV treatment, switching to an alternative 
ARV and cautious use of a statin or fibrate as necessary should 
be considered. Simvastatin is contraindicated in patients using 
protease inhibitors.
Unusual conditions
Unexplained cutaneous or tendinous deposits (xanthomata), 
very premature vascular disease, some endocrine, metabolic 
and neurological disorders constitute reasons for referral. 
Unusually low TC (<2.5mmol/l), LDL-C (<1.5mmol/l), 
HDL-C (<0.7mmol/l) or unusually high TG (>10mmol/l), TC 
(>15mmol/l), LDL-C (>12mmol/l), HDL-C (>2.5mmol/l) also 
deserve special consideration.
TABLE 5: Practical guide to initiating statins depending on baseline LDL-C and target LDL-C values*
 Goal: <1.8 mmol/l   Goal: <2.5 mmol/l   Goal: <3.0 mmol/l 
Starting 
LDL-C (mmol)
>6.2
5.2 - 6.2
4.4 - 5.2
3.9 - 4.4
3.4 - 3.9
2.9 - 3.4
2.3 - 2.9
1.8 - 2.3
% reduction 
required
>70#
65 - 70#
60 - 65#
55 - 60
45-55
35 - 45
22 - 35
<22
% reduction 
required
>60#
50 - 60
40 - 50
35 - 40
25 - 35
10 - 25
<10
-
% reduction 
required
>55
40 - 55
30 - 45
25 - 30
10 - 25
<10
-
-
Statin dose
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 10 mg 
Atorvastatin 40 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 20 mg
Lovastatin 40 mg
Fluvastatin 80 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg
Lovastatin 10 mg
Pravastatin 20 mg
Fluvastatin 40 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg
Lovastatin 10 mg
Pravastatin 20 mg
Fluvastatin 40 mg
Statin dose
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 20 mg 
Atorvastatin 40 mg
Rosuvastatin 10 mg
Atorvastatin 20 mg
Simvastatin 40 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 20 mg
Lovastatin 40 mg
Fluvastatin 80 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg
Lovastatin 20 mg
Pravastatin 40 mg
Fluvastatin 80 mg
Any statin at lowest 
dose
Any statin at lowest 
dose
Statin dose
Rosuvastatin 40 mg 
Atorvastatin 80 mg
Rosuvastatin 10 mg 
Atorvastatin 20 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 20 mg
Lovastatin 40 mg
Fluvastatin 80 mg
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg
Lovastatin 20 mg
Pravastatin 40 mg
Fluvastatin 80 mg
Any statin at lowest 
dose
Any statin at lowest 
dose
*Based on weighted average of pooled analysis at starting dose. Dose should be titrated according to response.  #Maximum LDL-C reduction achievable with high-dose statin 
monotherapy is 50 - 60%. To achieve a reduction in LDL-C of >60%, another cholesterol-lowering agent in addition to statin therapy may be required.
Adapted from Reiner Ž, et al., Eur Heart J 2011;32:1769-1818(3) and Weng T-C, et al., J Clin Pharm Ther 2010;35:139-151.(21)
LDL-C = low-density lipoprotein cholesterol.
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CONCLUSIONS: IMPLEMENTATION OF THE 
2011 GUIDELINES
In order to implement the guidelines, we propose a simple 
chart that has been updated to accommodate the new 
Framingham CVD risk tables (Appendix 1). The chart is a guide 
to management only and should not replace an individualised 
assessment and treatment plan based on the clinical judgement 
of the doctor. We encourage the reader to read the 2011 
European guidelines in full, which may be accessed on the ESC 
website www.escardio.org/guidelines. We hope that dissemina-
tion of these guidelines will go some way towards helping to 
reduce the burden of CVD in South Africa.
MECHANISM OF GUIDELINE PREPARATION
In October 2011 a broad-based group of participants from the 
medical and allied health community, medical funders, pharma-
ceutical companies, the Department of Health, the Board of 
Health Funders and the Heart and Stroke Foundation met 
together with Professor Marja-Riitta Taskinen in Sandton, 
Johannesburg, to examine and discuss the joint ESC/EAS 
dyslipidaemia guidelines. Professor Taskinen is a co-author and 
Task Force Member of these guidelines and attended on behalf 
of the European Athero-sclerosis Society.
The following day a writing committee met to construct the 
South African Consensus Document.
Additional delegates attending the Dyslipidaemia Guidelines 
Meeting Discussion Group were Dr A. Amod (SEMDSA), 
Ms G. Bartlett (Universal Health), Ms U. Behrtel, Dr S. Bhana 
(Netactive), Ms M. Campbell (Discovery), Mr D. Craythorne 
(Cipla), Mr A. Dansay (PharmaDynamics), Ms L. Doms 
(Medscheme), Ms A. du Plessis (Vital Health), Ms U. du Preez 
(Astra Zeneca), Dr R. Espaillat (Abbott Laboratories), 
Dr C. Golding (Solal Labora-tories), Ms K. Jamaloodien 
(National Department of Health), Dr D. Katzman (MSD), 
Dr S. Kahn, Mr M. Lambert (Aspen), Dr M. Makotoko, 
Mr M. Mashego (Adcock Ingram), Ms Y. Misra (MediKredit), 
Dr M. Mpe, Dr V. Mungai-Singh (Heart and Stroke Foundation), 
Ms L. Naidoo (Sanlam Healthcare), Ms N. Nel, Dr R. Patel 
(Board of Healthcare Funders), Ms D. Pithey (MSD), Mr J. Rall 
(Ranbaxy), Dr J. Snyman (Agility Global Health Solutions), 
Dr M. Sussman (SA Heart), Dr M. Swanepoel (Medihelp), 
Professor J.P. van Niekerk (South African Medical Journal) and 
Ms L. Xiphu (QUALSA/Metropolitan).
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APPENDIX 1: Cardiovascular risk stratifi cation
Framingham 10-year risk assessment chart for patients without diabetes
Risk of CVD: coronary heart disease, stroke, peripheral artery disease, or heart failure
 Systolic BP – on antihyper-
tensive treatment (mmHg) 
<120
120 - 129
130 - 139
140 - 159
≥160
?
Estimate of 10-year risk of CVD for men
Age (yrs) 
30 - 34
35 - 39
40 - 44
45 - 49
50 - 54
55 - 59
60 - 64
65 - 69
70 - 74
75 years or older
Total cholesterol (mmol/l) 
<4.10
4.10 - 5.19
5.2 - 6.19
6.20 - 7.20
>7.20
HDL-cholesterol (mmol/l) 
≥1.50
1.30 - 1.49
1.20 - 1.29
0.90 - 1.19
<0.90
  Systolic BP – untreated (mmHg) 
<120
120 - 129
130 - 139
140 - 159
≥160
 Smoker 
No
Yes
Points 
0
2
5
6
8
10
11
12
14
15
Points 
0
1
2
3
4
Points 
-2
-1
0
1
2
Points 
-2
0
1
2
3
Points 
0
2
3
4
5
Points 
0
4
 Systolic BP – on antihyper-
tensive treatment (mmHg) 
<120
120 - 129
130 - 139
140 - 149
150 - 159
≥160
Estimate of 10-year risk of CVD for women
Age (yrs) 
30 - 34
35 - 39
40 - 44
45 - 49
50 - 54
55 - 59
60 - 64
65 - 69
70 - 74
75 years or older
Total cholesterol (mmol/l) 
<4.10
4.10 - 5.19
5.2 - 6.19
6.20 - 7.20
>7.20
HDL-cholesterol (mmol/l) 
≥1.50
1.30 - 1.49
1.20 - 1.29
0.90 - 1.19
<0.90
  Systolic BP – untreated (mmHg) 
<120
120 - 129
130 - 139
140 - 149
150 - 159
≥160
 Smoker 
No
Yes
Points 
0
2
4
5
7
8
9
10
11
12
Points 
0
1
3
4
5
Points 
-2
-1
0
1
2
Points 
-3
0
1
2
4
5
Points 
-1
2
3
5
6
7
Points 
0
3
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APPENDIX 1: Cardiovascular risk stratifi cation continued
Point totals indicate the 10-year risk of cardiovascular disease (coronary, cerebrovascular and peripheral arterial disease, and heart failure).
           Low risk                          Moderate risk                          High risk                          Very high risk
Adapted from D’Agostino RB, et al., General cardiovascular risk profi le for use in primary care: The Framingham Heart Study. Circulation 2008;117:743-753(9) 
and Mosca L, et al., Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A guideline from the American Heart 
Association. Circulation 2011;123:1243-1262.(8)
Management and cholesterol goals according to Framingham risk score
Category 1: Individuals considered to be at very high risk who do not need scoring
1. Established atherosclerosis
  coronary heart disease
  cerebrovascular disease
  peripheral vascular disease
2.  Type 2 diabetes*
3.  Type 1 diabetes with target organ damage
4. Chronic kidney disease (GFR <60 ml/min/1.73m2)
5. Genetic dyslipidaemias (e.g. familial hypercholesterolaemia)
*In patients with type 2 diabetes younger than age 40 years or with duration of diabetes <10 years and no other CVD risk factors, the LDL-C target is <2.5mmol/l.
Goal†
LDL cholesterol <1.8mmol/l**
**and/or a >50% LDL-C reduction when the LDL-C target cannot be achieved
Points total for men
Points total 
-3 or less
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18 or more
10-year risk (%) 
<1
1.1
1.4
1.6
1.9
2.3
2.8
3.3
3.9
4.7
5.6
6.7
7.9
9.4
11.2
13.2
15.6
18.4
21.6
25.3
29.4
>30
Points total for women
Points total 
-2 or less
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21 or more
10-year risk (%) 
<1%
1.0
1.1
1.5
1.8
2.1
2.5
2.9
3.4
3.9
4.6
5.4
6.3
7.4
8.6
10.0
11.6
13.5
15.6
18.1
20.9
24.0
27.5
>30
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APPENDIX 1: Cardiovascular risk stratifi cation continued
Category 2:‡ Risk scoring required – use the Framingham risk tables§
 Use correct gender table Score
 1. Age 1. ________
 2. Total cholesterol* 2. ________
 3. Non-smoker/smoker 3. ________
 4. HDL-C 4. ________ 
 5. Systolic BP 5. ________
Limitations of the Framingham Risk Assessment Score charts
1.  Patients who are classifi ed in the very high-risk category do not require further risk scoring for management decisions. Risk will also be underestimated 
in patients who have a markedly elevated single risk factor (e.g. severe hypertension: systolic BP >180mmHg and/or diastolic BP >110mmHg), or 
associated target organ damage.
2.  Severe hypercholesterolaemia and hypertriglyceridaemia: The Framingham risk assessment chart is only accurate up to total cholesterol values of 
7.25mmol/l and cannot be used for patients with TC levels above this value. It also does not apply to hypertriglyceridaemia (triglyceride >5mmol/l).
3.  Family history of early atherosclerotic disease is not taken into account. Clinicians should use their judgement in deciding whether to place a patient with 
an impressive family history in the high-risk category regardless of their Framingham score.
4. Despite these factors being important risk factors for CVD, impaired glucose tolerance and abdominal obesity are not taken into account in the risk score.
†Pharmacological treatment is required if LDL cholesterol remains above these levels despite lifestyle modification. At present statins are first-line drugs for lowering LDL cholesterol.
‡Secondary causes of dyslipidaemia should be excluded before progressing to risk assessment.  §See limitations of Framingham Risk Assessment Score on this page.
*Total cholesterol level is used to assign risk score and may be used for follow-up cholesterol measurement in patients on drug therapy, but LDL cholesterol is the target of treatment. 
LDL-C = low-density lipoprotein cholesterol. HDL-C = high-density lipoprotein cholesterol. TG = triglyceride. CHD = coronary heart disease. CVD = cardiovascular disease. 
BP = blood pressure. GFR = glomerular filtration rate. TC = total cholesterol.
Initial CVD risk <3%
Institute lifestyle changes
Consider statin if LDL-C 
persistently >4.9mmol/l
Initial CVD risk 3-<15%
Institute lifestyle changes
Consider statin if LDL-C 
persistently >3.0mmol/l
Initial CVD risk 15-<30%
Institute lifestyle changes
Consider statin if LDL-C 
>2.5mmol/l
Start statin immediately if 
LDL-C >2.5mmol/l
Goal†
LDL-C <2.5mmol/l
Goal†
LDL-C <3.0mmol/l
Initial CVD risk >30%
Institute lifestyle changes
Start statin immediately
Goal†
LDL-C <1.8mmol/l
10-year CVD event risk: ________%
Conversion from mg/dl
Cholesterol Triglyceride
mmol/l = mg/dl × 0.0259.  mg/dl = mmol/l × 38.6 mmol/l = mg/dl × 0.0113.  mg/dl = mmol/l × 88.5
117
A
ut
um
n 
20
12
Vo
lu
m
e 
9 
• 
N
um
be
r 2
APPENDIX 2: South African Heart Association/LASSA guidelines for lifestyle modifi cation for patients with dyslipidaemia
1.  Stop smoking and avoid exposure to environmental tobacco smoke.
2. Increase your physical activity. Try to do exercise of moderate intensity, such as brisk walking, for at least 30 minutes on all or most days of the week.
3.  Achieve and maintain ideal body weight.
4.  Reduce your intake of saturated fats, trans-fats and cholesterol. Avoid eating fatty meats, processed meats, chicken skin, processed meats, confectionery 
such as pies, pastries and cookies, fast foods, deep-fried potato chips (‘slap chips’), butter, ghee, cream, hard cheeses and salty crackers.
5.  Replace saturated fats with unsaturated fats. Avoid the use of hard margarines, butter and ghee for cooking or adding to food. Use unsaturated fats such 
as canola oil, olive oil and sunfl ower oil for cooking. Use oils sparingly and avoid all deep-frying of food. Remove all visible fat before cooking. Increase 
your intake of all types of fi sh, especially oily fi sh such as sardines and salmon, to a minimum of twice a week.
6.  Increase your intake of fi bre, especially soluble fi bre. Include foods such as oats, fresh fruit and legumes (dry beans, soya beans, chickpeas, all types of 
lentils). Include a minimum of fi ve portions of fresh fruit and vegetables in your daily diet.
7.  Replace all refi ned carbohydrate types of foods with foods high in fi bre, such as whole grains. Avoid eating products made from white fl our, such as 
white bread and rolls, pizzas, vetkoek, samoosas, pies, prego rolls and bakery items such as cakes and biscuits. Incorporate whole-grain foods such as 
oats, barley, stampkoring (pearl wheat), crushed wheat, samp and beans, brown rice, brown/wild rice, whole-grain breakfast cereals, health and seed 
breads.
8.  Avoid foods high in free sugars (sucrose, high-fructose corn syrup, fructose) such as sweets, chocolates, all fi zzy soft drinks, fruit juices, all fl avoured and 
sweetened waters, low-fat sweetened milky drinks.
9.  If you consume alcohol, do so in moderation – no more than 2 drinks for men and 1 drink for women per day.
10.  Avoid adding salt to food after cooking. Choose and prepare foods with little or no salt by using more herbs and spices.
11.  For dietary lifestyle intervention all patients should ideally be referred to a registered dietician.
